By Rishika Sadam and Kashish Tandon HYDERABAD (Reuters) -Danish drugmaker Novo Nordisk launched its blockbuster weight-loss drug Wegovy in the world's most populous nation, in a move that will challenge rival Eli Lilly's Mounjaro,

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ending of its deal with Hims & Hers jeopardizes the healthcare platform's goal to lead the weight loss market.

Wegovy will be available in India in five strengths. While the lower doses (0.25 mg, 0.5 mg, and 1 mg) will be priced at ₹17,345 for a month (four weekly doses), the higher doses, 1.7 mg and 2.4 mg, will have price tags of ₹24,280 and ₹26,050, respectively, for a month’s treatment.